Director/PDMR Shareholding

RNS Number : 4305Z

Creo Medical Group PLC

31 August 2018

 

31 August 2018

Creo Medical Group plc

(the "Company")

Director/PDMR Dealing

Further to the completion of the Placing which occurred yesterday, and as detailed in the Company's announcement dated 13 July 2018, Craig Gulliford, Chief Executive Officer, and Chris Hancock, Chief Technology Officer, each sold 480,000 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") on 30 August 2018 at the Placing Price of £1.25 per Ordinary Share.

Following these trades, Mr Gulliford holds 609,886 Ordinary Shares representing approximately 0.51% of the Company's enlarged issued share capital and Mr Hancock holds 4,400,046 Ordinary Shares, representing approximately 3.67% of the Company's enlarged issued share capital.

Capitalised terms used, but not defined, in this announcement shall have the same meaning as set out in the Circular.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Craig Gulliford
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	213800H188ZDCWWXFA21
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.1 pence each GB00BZ1BLL44
b)	Nature of the transaction	Sale of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s)  £1.25  480,000
d)	Aggregated information - Aggregated volume - Price	n/a - single transaction
e)	Date of the transaction	30 August 2018
f)	Place of the transaction	London Stock Exchange

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Chris Hancock
2	Reason for the notification
a)	Position/status	Chief Technology Officer
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	213800H188ZDCWWXFA21
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.1 pence each   GB00BZ1BLL44
b)	Nature of the transaction	Sale of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s)  £1.25  480,000
d)	Aggregated information - Aggregated volume - Price	n/a - single transaction
e)	Date of the transaction	30 August 2018
f)	Place of the transaction	London Stock Exchange

Contacts

Creo Medical:	Cenkos:	FTI Consulting:
Richard Rees [phone]  [e-mail]	Mark Connelly (NOMAD) Michael Johnson / Russell Kerr (Sales) [phone]	Brett Pollard / Mo Noonan [phone] [e-mail]

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring the CROMA surgical system to market through a suite of medical instruments which the Company has designed, initially for GI therapeutic endoscopy, an area with high unmet needs. The CROMA system will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

 

END

 

 

DSHLLFFITTILVIT